ライフサイエンスコーパス: cutaneous

1 ition characterized by ocular, auditory, and cutaneous abnormalities, with major complications of inf

2 rescribed following incision and drainage of cutaneous abscesses.

3 propose that cutaneous activation of TRPV1(+) sensory neurons by prot

4 re not at a higher risk of presenting with a cutaneous adverse drug reaction compared with non-sulfon

5 Cutaneous adverse reaction associated with entecavir has

6 nhibit EGFR and MEK is frequently limited by cutaneous adverse reactions, most commonly acne-like eru

7 fonamide moiety and a high reporting rate of cutaneous AEs and indicated that the risk of such AEs wa

8 gap, an analysis of postmarketing reports of cutaneous AEs for drugs with and without a sulfonamide g

9 that individuals with HSAN III rely more on cutaneous afferents around the elbow.

10 ked by activity in low threshold, presumably cutaneous afferents, whereas LAI and PAS require activit

11 T cells into Foxp3(+) Treg in response to a cutaneous Ag (OVA).

12 with other classes of ALCL, such as primary cutaneous ALCL and systemic type ALK+ and ALK- ALCL.

13 Nasal and cutaneous allergen challenge tests were performed annual

14 Using a model of cutaneous allergen exposure, we show that allergens dire

15 to both short-term and long-term changes in cutaneous allergic and other inflammatory processes.

16 percutaneous sensitized AD model and passive cutaneous anaphylaxis (PCA) model on VAD and vitamin A s

17 ur in vitro data, mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis w

18 rom vascular edema induced by either passive cutaneous anaphylaxis or direct challenge with histamine

19 istamine release assay and the human passive cutaneous anaphylaxis test were utilized to study the ab

20 pressed peanut-specific IgE-mediated passive cutaneous anaphylaxis, and attenuated dansyl IgE-mediate

21 , we report organizational properties of the cutaneous and central axonal projections of the five pri

22 biologics, could enable a broad range of non-cutaneous and cutaneous drug delivery applications, incl

23 on, allergens, water hardness) and internal (cutaneous and gut microbiota and host cell interaction)

24 ouble-stranded DNA tumor virus infecting the cutaneous and mucosal epithelium.

25 to separate out the relative contribution of cutaneous and muscle afferent input to each effect.

26 Physiological differences in effects of cutaneous and muscle afferent inputs on face M1 excitabi

27 In the face, cutaneous and muscle afferents are segregated in the tri

28 cluded a wide range of systemic therapies in cutaneous and noncutaneous melanoma.

29 cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary inflammation, chondritis, and va

30 es such as blended reactions (coexistence of cutaneous and respiratory symptoms) or food-dependent NS

31 aneous scratching and significantly aberrant cutaneous and systemic immune responses lasting for week

32 ly life-threatening disorder presenting with cutaneous and systemic neutrophilia.

33 ated as potential vaccine candidates against cutaneous and visceral leishmaniasis, respectively.

34 ne is an FDA approved oral drug for treating cutaneous and visceral leishmaniasis.

35 In 21 cutaneous and/or visceral Kaposi's sarcoma cases, occurr

36 Leishmania (L.) infantum causes visceral, cutaneous, and mucosal leishmaniasis in humans and canin

37 role, for example, in a number of allergic, cutaneous, and vascular diseases.

38 n injury inhibits the T(H)1 cell response to cutaneous antigen exposure in AD.

39 ng been used as a drug delivery platform for cutaneous applications and have benefits over comparable

40 The richness and diversity of such cutaneous bacterial communities are known to be shaped b

41 d activation of local mast cells also clears cutaneous bacterial infection, promotes healing, and pro

42 ormal epidermal differentiation and impaired cutaneous barrier function observed in patients with ARC

43 a multipronged approach, not only restoring cutaneous barrier function, microbial flora, and immune

44 cholesterol, and a past history of numerous cutaneous basal and squamous cell carcinomas.

45 by the inability of keratinocytes to control cutaneous beta-HPV infection and a high risk for non-mel

46 mpact translational research methodology for cutaneous biology research and foster multidisciplinary

47 to seminal advances in our understanding of cutaneous biology.

48 t of prostate cancer, the most prevalent non-cutaneous cancer in men.

49 SATB1 and CD30 coexpression distinguished cutaneous CD30(+) lymphoproliferative disorders from MF

50 The term "primary cutaneous CD4(+) small/medium T-cell lymphoma" was modif

51 um T-cell lymphoma" was modified to "primary cutaneous CD4(+) small/medium T-cell lymphoproliferative

52 Cutaneous changes seem to start around hair follicles an

53 model of VCA tolerance, and the kinetics of cutaneous chimerism in both of these populations in VCAs

54 Biofilm infection caused degradation of cutaneous collagen, specifically collagen 1 (Col1), with

55 ulation of immune response and regulation of cutaneous commensal bacteria.

56 The cutaneous cytokine signature was further evaluated by re

57 We hypothesize that a high cutaneous D816V(+) mast cell burden alters the skin micr

58 sitivity model in which mTORC2 was absent in cutaneous DCs.

59 ractional laser ablation can be used for the cutaneous delivery of OS2966 and now preclinical/clinica

60 sory TRP-neuropeptide pathway in influencing cutaneous discomfort is revealed, indicating the therape

61 ide insight into disease pathomechanisms and cutaneous disease activity.

62 ated respiratory disease, NSAIDs-exacerbated cutaneous disease and NSAIDs-induced urticaria/angioedem

63 d ultraviolet B light (UVB) exposure worsens cutaneous disease and precipitates systemic flares of di

64 In humans, cutaneous disease predominated (n=100/137, 73%), followe

65 tion and advancement of our understanding of cutaneous diseases.

66 ld enable a broad range of non-cutaneous and cutaneous drug delivery applications, including multicom

67 e awareness of clinicians on the spectrum of cutaneous drug reaction related to entecavir therapy.

68 Cutaneous dysbiosis is implicated in hidradenitis suppur

69 plasticity as measured by the application of cutaneous electrical stimulation of varying intensity an

70 st in a delayed manner as different forms of cutaneous eruptions or liver injury consistent with prim

71 relatively uncommon but included discomfort, cutaneous erythema, blistering, eyelash loss, and floate

72 (hypertrophic scar or keloid) or to prevent cutaneous fibrosis, such as scleroderma.

73 pic approach developed enteral or pancreatic-cutaneous fistulae compared with 28.1% of the patients w

74 This cutaneous flare reaction did not result in treatment dis

75 er blocks and spring cells, which emphasized cutaneous-force and proprioceptive feedback, respectivel

76 , and T cell receptor (TCR) sequencing on 29 cutaneous gammadelta lymphomas.

77 Primary cutaneous gammadelta T cell lymphomas (PCGDTLs) represen

78 e able to penetrate human skin to knock down cutaneous gene targets.

79 isolated single-cell suspensions from acute cutaneous GVHD and subjected them to genotype, transcrip

80 Antibodies are key to cutaneous host defense and inflammation.

81 demiological and experimental data implicate cutaneous human papillomavirus infection as co-factor in

82 Although many high-risk mucosal and cutaneous human papillomaviruses (HPVs) theoretically ha

83 like their counterparts in lymphoid tissues, cutaneous IgM-secreting cells were completely dependent

84 The formation of the cutaneous immune arsenal begins before birth and evolves

85 ogies have illuminated the complexity of the cutaneous immune cells and their functions in maintainin

86 The mechanisms how AhR activates or inhibits cutaneous immune responses remain controversial, owing t

87 integrating the role of commensal bacteria, cutaneous immune responses, and complement dysregulation

88 To understand this process, the study of cutaneous immunology has focused on immune responses tha

89 Typically starting in early adulthood, cutaneous inflamed nodules, abscesses and pus-dischargin

90 ythematosus (SLE), yet mechanisms that drive cutaneous inflammation in SLE are not well defined.

91 induce IFN production, could play a role in cutaneous inflammation in SLE.

92 In mice, topical ACHP prevented the cutaneous inflammation induced by topical phorbol myrist

93 Cutaneous inflammation is recurrent in systemic lupus er

94 Rag2(R229Q) mice is associated with enhanced cutaneous inflammation on local and systemic administrat

95 ersed imiquimod-established chronic itch and cutaneous inflammation.

96 fficient to initiate IL-1 receptor-dependent cutaneous inflammatory disease, but the source of IL-1 a

97 Granuloma annulare (GA) is a common cutaneous inflammatory disorder characterized by macroph

98 ectodermal dystrophy suffer from early-onset cutaneous inflammatory lesions accompanied by an infiltr

99 We studied cutaneous innervation in 30 patients with chronic compre

100 ediolateral compression, compared with their cutaneous innervation patterns, and these central projec

101 Cutaneous inputs may exert a paucisynaptic inhibitory ef

102 , scoliosis, rigid spine, dysmorphic facies, cutaneous involvement, respiratory failure, and in the o

103 alian skin in response to infection with the cutaneous Leishmania pathogen.

104 t contribute to the efficacy of treatment of cutaneous leishmaniasis (CL) are not fully understood.

105 Anthroponotic cutaneous leishmaniasis (CL) caused by Leishmania tropic

106 The treatment of cutaneous leishmaniasis (CL) in Brazil by pentavalent an

107 Cutaneous leishmaniasis (CL) is a neglected tropical dis

108 role played by natural killer (NK) cells in cutaneous leishmaniasis (CL) remains poorly understood.

109 vated or decrease risk in the development of cutaneous leishmaniasis (CL).

110 e considered a strategy for the treatment of cutaneous leishmaniasis disease in combination with anti

111 Protective immunity to cutaneous leishmaniasis is mediated by IFN-gamma-secreti

112 t is highly expressed in human patients with cutaneous leishmaniasis lesions and promotes granzyme B-

113 being able to acquire parasites from active cutaneous leishmaniasis lesions, sustain mature infectio

114 tinib protecting mice from developing severe cutaneous leishmaniasis lesions.

115 In cutaneous leishmaniasis, the immune response is not only

116 In cutaneous leishmaniasis, the protein of L. major, named

117 Leishmania major causes cutaneous leishmaniasis.

118 tion for treating individuals suffering from cutaneous leishmaniasis.

119 eir ability to infect macrophages and induce cutaneous lesions in mice.

120 Cutaneous lupus erythematosus lesional skin microarray d

121 We show here that active cutaneous lupus erythematosus lesions are highly coloniz

122 population and cytokine profiles in lesional cutaneous lupus erythematosus skin could affect antimala

123 n tumors developed preferentially within the cutaneous lupus inflammation without scarring in MRL/lpr

124 Knowledge of the etiology of cutaneous lupus is rapidly evolving.

125 activation, respectively, within skin-homing/cutaneous lymphocyte antigen (CLA)(+) versus systemic/CL

126 abundantly express the skin homing receptors cutaneous lymphocyte associated antigen and CCR4 (Ccr4),

127 Primary cutaneous lymphomas encompass a wide spectrum of rare ly

128 clinical outcomes for patients with advanced cutaneous malignancies.

129 t recipients (OTRs) are at increased risk of cutaneous malignancy.

130 s may be studied in relevant mouse models of cutaneous malignancy.

131 Cutaneous malignant melanoma is an aggressive cancer of

132 regulators of gene expression in the TME of cutaneous malignant peripheral nerve sheath tumor (C-MPN

133 Mendelian disorders with cutaneous manifestations comprise a genotypically hetero

134 me is a potential therapeutic target for the cutaneous manifestations of autoimmune diseases.

135 The impact of altered gut homeostasis in the cutaneous manifestations of OS remains to be clarified.

136 e in ISM is stable and comparable to that of cutaneous mastocytosis (CM).

137 Release of IL-13 by cutaneous MCs in response to mechanical skin injury inhi

138 s that express Gpr83 are highly sensitive to cutaneous mechanical stimuli and receive strong synaptic

139 althy controls, arguing for sensitization of cutaneous mechano- and heat-sensitive C-fibers in CP.

140 Meissner's corpuscles (MCs) are cutaneous mechanoreceptors found in glabrous skin and ar

141 dle afferents but do have essentially normal cutaneous mechanoreceptors.

142 which we attribute to the presence of intact cutaneous mechanoreceptors.

143 Cutaneous mechanosensory neurons are activated by mechan

144 nsmitting mechanical strain from the skin to cutaneous mechanosensory neurons.

145 Diagnoses included conjunctival and eyelid cutaneous melanoma (85 and 42 patients, respectively), s

146 a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7

147 levels of active TGF-beta1 in patients with cutaneous melanoma (CM), assess their relationship with

148 ients with obstructive sleep apnea (OSA) and cutaneous melanoma (CM).

149 these signatures onto the collection of TCGA cutaneous melanoma and found that poorly differentiated

150 is the most common driver mutation in human cutaneous melanoma and is frequently accompanied by loss

151 (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma as per American Joint Committee on Ca

152 The survival of patients with cutaneous melanoma can be accurately predicted using jus

153 for only about half of all densely affected cutaneous melanoma families, and the causes of familial

154 These findings provide insights into cutaneous melanoma genetic architecture, reinforcing the

155 gical factors such as ultraviolet radiation, cutaneous melanoma has a strong genetic component.

156 vitreous debris in the context of metastatic cutaneous melanoma includes intravitreal metastasis, and

157 Cutaneous melanoma is one of the most aggressive cancers

158 Cutaneous melanoma metastatic to the vitreous is very ra

159 with identifying potential new pathways for cutaneous melanoma pathogenesis.

160 d from whole-exome sequencing analysis of 98 cutaneous melanoma patients from 27 families.

161 ysis of 2,183 population-ascertained primary cutaneous melanoma patients, clinical, demographic, and

162 Genetic risks for cutaneous melanoma range from rare, high-penetrance muta

163 Most genetic susceptibility to cutaneous melanoma remains to be discovered.

164 1 potential secondary loci for a total of 85 cutaneous melanoma susceptibility loci.

165 significantly higher mean polygenic load for cutaneous melanoma than unrelated cases or melanoma-free

166 hough UM metastases are less responsive than cutaneous melanoma to chemotherapy or immune checkpoint

167 We used a polygenic risk score for cutaneous melanoma to compare families without known hig

168 ent, and outcome of patients with metastatic cutaneous melanoma to the vitreous.

169 Over half of cutaneous melanoma tumors have BRAF(V600E/K) mutations.

170 IIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pem

171 vitreous debris in the context of metastatic cutaneous melanoma would benefit from evaluation by an o

172 Cancers, including cutaneous melanoma, can cluster in families.

173 ighly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoin

174 (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma, per American Joint Committee on Canc

175 For patients with primary cutaneous melanoma, the risk of sentinel node (SN) metas

176 ith resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or

177 d be offered to patients with BRAF wild-type cutaneous melanoma, while those three regimens or combin

178 ltrating lymphocytes in breast carcinoma and cutaneous melanoma.

179 e offered the same therapies recommended for cutaneous melanoma.

180 ITF(E318K) variant confers moderate risk for cutaneous melanoma.

181 s are the most common genetic alterations in cutaneous melanoma.

182 linically and genetically distinct from skin cutaneous melanoma.

183 or against the use of neoadjuvant therapy in cutaneous melanoma.

184 iated by a mutation in GNAQ or GNA11, unlike cutaneous melanomas, which usually harbour a BRAF or NRA

185 ; <= 1 mm) constitute 70% of newly diagnosed cutaneous melanomas.

186 , breakend hypermutation, and acral, but not cutaneous, melanomas.

187 Using ex vivo skin explants from cutaneous MF tumors as well as Sezary cells derived from

188 ffective tool for in situ engineering of the cutaneous microenvironment to enable diverse immunizatio

189 (antigen plus adjuvant) vaccines to the same cutaneous microenvironment.

190 VD but does not affect NO-mediated VD in the cutaneous microvasculature.

191 of allergens, irritants, and microbes into a cutaneous milieu that facilitates the induction of type

192 Intriguingly, positivity with the cutaneous MnPV was accompanied by a strong seroresponse

193 mild endocardial fibroelastosis (n = 1) and cutaneous neonatal lupus (n = 4).

194 ell carcinoma (EpSCC) is a relatively common cutaneous neoplasm with a poor prognosis.

195 precisely, in these cases the medial dorsal cutaneous nerve got injured during the fascial opening o

196 , and translational research perspectives in cutaneous neuroendocrinology and argue that greater emph

197 The proportion of cutaneous, neurologic, and other complications was 6.40%

198 Proportions of cutaneous, neurologic, and other complications were 6.40

199 We sought to comprehensively analyze cutaneous NK-cell transcriptomic signatures in AD, and t

200 viously characterized central projections of cutaneous nociceptive A and C fibers, selectively labele

201 at sea lampreys (Petromyzon marinus L.) have cutaneous papillae located around the oral disk, nostril

202 ssess SCCs that are particularly numerous on cutaneous papillae.

203 nial aneurysms, ipsilateral to an impressive cutaneous phenotype.

204 This study advanced our understanding of how cutaneous plantar sensation can be used to acquire actio

205 lasma cells in inflammatory skin diseases or cutaneous plasma cell malignancies.

206 o of potential relevance for manipulation of cutaneous plasma cells in inflammatory skin diseases or

207 n the genomic and clinical features of these cutaneous polyomaviruses.

208 We found that cutaneous psoriasis and psoriatic arthritis both exhibit

209 tion studies to estimate the heritability of cutaneous psoriasis, psoriasis vulgaris and psoriatic ar

210 ity, with a greater contribution coming from cutaneous psoriasis.

211 ell numbers and epidermal BMP7 expression in cutaneous psoriatic lesions and show that unlike Treg ce

212 ly induced within epidermal keratinocytes in cutaneous psoriatic lesions, and BMP7 instructs monocyti

213 ight allow to therapeutically interfere with cutaneous psoriatic manifestations.

214 ganglionic axons connect to iWAT via lateral cutaneous rami (dorsolumbar iWAT portion) and the lumbar

215 fficulty of efficient integration of complex cutaneous receptor-emulating circuitry and the lack of a

216 unnel release is associated with significant cutaneous reinnervation, which correlates with the degre

217 Here, we report the largest cutaneous SCC meta-analysis to date, representing six in

218 leotide polymorphisms (SNPs) associated with cutaneous SCC.

219 rmatitis (AD), characterized by pruritis and cutaneous sensitization to allergens, including foods, i

220 In addition to promoting cutaneous sensitization to foods, scratching may promote

221 l for a reassessment of basic assumptions in cutaneous sensory perception and sheds new light on the

222 erate to convey thermal, tactile and noxious cutaneous signals from the spinal cord to the lateral pa

223 Primary cutaneous signet-ring cell/histiocytoid carcinoma of the

224 gy report confirmed the diagnosis of primary cutaneous signet-ring cell/histiocytoid carcinoma.

225 ulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients

226 Cutaneous somatosensory modalities play pivotal roles in

227 Keratinocyte skin cancer, comprising cutaneous squamous (cSCC) and basal cell carcinoma, is t

228 The role of lncRNA LINC00346 in cutaneous squamous carcinoma (cSCC) was examined.

229 Nonmelanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by so

230 Nonmelanoma skin cancer such as cutaneous squamous cell carcinoma (cSCC) is the most com

231 perineural invasion (PNI) and desmoplasia on cutaneous squamous cell carcinoma (CSCC) recurrence and

232 terfering RNA screen to identify targets for cutaneous squamous cell carcinoma (cSCC) therapy in the

233 the cellular composition and architecture of cutaneous squamous cell carcinoma (cSCC), we combined si

234 kidney transplant recipient with metastatic cutaneous squamous cell carcinoma (CSCC).

235 ients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rate

236 Cutaneous squamous cell carcinoma (cuSCC) is the second

237 ceptibility to ultraviolet radiation-induced cutaneous squamous cell carcinoma (cuSCC).

238 Cutaneous squamous cell carcinoma (SCC) is one of the mo

239 sk of basal cell carcinoma (BCC) or invasive cutaneous squamous cell carcinoma (SCC).

240 th histologically confirmed locally advanced cutaneous squamous cell carcinoma and an Eastern Coopera

241 ty profile in patients with locally advanced cutaneous squamous cell carcinoma for whom there was no

242 Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis wi

243 asing incidence rates, prognosis of invasive cutaneous squamous cell carcinoma remains poor, mainly d

244 rogression and metastasis of mouse and human cutaneous squamous cell carcinoma.

245 cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma.

246 itumour activity in patients with metastatic cutaneous squamous cell carcinoma.

247 ent precancerous lesion that can progress to cutaneous squamous cell carcinoma.

248 nus human papillomaviruses (beta-HPVs) cause cutaneous squamous cell carcinomas (cSCCs) in a subset o

249 infection as co-factor in the development of cutaneous squamous cell carcinomas (cSCCs), particularly

250 to repurpose phenformin for the treatment of cutaneous squamous cell carcinomas.

251 As a result, cutaneous stimulation produced unbalanced responses favo

252 Recovery of responses to cutaneous stimuli in the area 3b hand cortex of monkeys

253 ction, later the episode, (2) respiratory or cutaneous symptoms or anaphylaxis related to NSAID, (3)

254 encodes a lysine 63 deubiquitinase and CYLD cutaneous syndrome, a skin tumour disorder, is caused by

255 In contrast with CYLD cutaneous syndrome-causative mutations, CYLDM719V exhibi

256 for the treatment of persistent or recurrent cutaneous T cell lymphoma.

257 Cutaneous T cell-mediated reactions classically occur mo

258 ence of infection, and a proportion of these cutaneous T cells can be locally activated upon injectio

259 d by the US Food and Drug Administration for cutaneous T-cell lymphoma (CTCL), including the leukemic

260 a 1 (PLCG1) is frequently mutated in primary cutaneous T-cell lymphoma (CTCL).

261 CuV was further detected in a proportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin

262 Cutaneous T-cell lymphoma is a form of non-Hodgkin lymph

263 Peripheral blood involvement by cutaneous T-cell lymphoma is typically assessed by flow

264 n 56 of 111 (50%) samples from patients with cutaneous T-cell lymphoma, accounting for 7-18,155 cells

265 rtant T-cell specific chromatin organizer in cutaneous T-cell lymphoma, whereas its expression and fu

266 ary syndrome are the most common subtypes of cutaneous T-cell lymphoma.

267 fungoides (MF), the most common subtypes of cutaneous T-cell lymphomas.

268 d is a potential future treatment option for cutaneous T-cell lymphomas.

269 (esophageal, gastric, and rectal distension, cutaneous thermal stimulation, and vulvar pressure) to e

270 In a cutaneous tissue injury murine model, we found that TLR4

271 uous mechanical forces by proprioceptors and cutaneous touch receptors.

272 pared for bovine masseter (fibre type I) and cutaneous trunci (fibre type II) muscles by Differential

273 myosin associated peak at 55.8 degrees C for cutaneous trunci and no peak for masseter (DSC), indicat

274 greater thermal denaturation of proteins in cutaneous trunci than in masseter (FTIR), supported by a

275 cell carcinoma (MCC) is the most aggressive cutaneous tumor without clearly defined treatment.

276 Haemophilus ducreyi are causative agents of cutaneous ulcer (CU) in yaws-endemic regions in the trop

277 lammatory condition characterized by chronic cutaneous ulcerations.

278 Cutaneous vaccination of mice using these MNAs induces m

279 eir application for effective multicomponent cutaneous vaccination.

280 We demonstrate that reflex cutaneous vasodilatation is impaired in older hyperchole

281 cular responses to thermal stress, including cutaneous vasodilation and vasoconstriction, are also af

282 ysis, CR was associated with M1b disease and cutaneous versus mucosal or acral primaries.

283 se (Vglut1-ChR2) to optogenetically activate cutaneous vesicular glutamate transporter 1 (Vglut1)-pos

284 However, it is unclear if these common cutaneous viruses are tumorigenic in the general populat

285 Epidemiology suggests that melanin inhibits cutaneous vitamin D(3) synthesis by UVR.

286 ed an average 75% reduction in the number of cutaneous warts.

287 d the patients were evaluated by cardiac and cutaneous work-up.

288 ad overview of the angiogenic process during cutaneous wound healing and the regulatory roles played

289 n-3-gallate (EGCG), a polyphenol, influences cutaneous wound healing because of its antiangiogenic, a

290 l wound healing, a process that differs from cutaneous wound healing by being faster and typically sc

291 Cutaneous wound healing is associated with the unpleasan

292 This review provides a brief overview of cutaneous wound healing with discussion on how extracell

293 ing ones, and it is an essential step during cutaneous wound healing, which supports cells at the wou

294 standard for testing of new therapeutics for cutaneous wound healing.

295 Prevention of aberrant cutaneous wound repair and appropriate regeneration of a

296 lating wound closure and inflammation during cutaneous wound repair.

297 Cutaneous wounds requiring tissue replacement are often

298 ine mostly inhibit the angiogenic process in cutaneous wounds, dopamine, the other member of the cate

299 tion of ischemic skeletal muscle, as well as cutaneous wounds, is impaired in mice with myeloid-speci

300 y were used to infect full-thickness porcine cutaneous wounds.